Claims

1. Use of a compound represented by a following chemical formula 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof, or mixtures thereof in the manufacture of a medicament for preventing, treating or alleviating non-alcoholic fatty liver disease:

[Chemical Formula 1]



wherein

A is 

, R_2 is C1-C6 strating or branced-chain alkyl;

B is 

, R_7 is C1-C6 straight or branched-chain alkyl; and

X is F.

2. The use according to claim 1, wherein the compound represented by the chemical formula 1 is

3-(4-(3-(1-(5-ethylpyrimidine-2-yl)piperidine-4-yl)propoxy)-2,6-difluorophenyl)-5-isop

ropyl-1,2,4-oxadiazole.

3. The use according to claim 1, wherein the non-alcoholic fatty liver disease is selected from the group consisting of simple fatty liver, non-alcoholic steatohepatitis, liver fibrosis and cirrhosis.

4. The use according to claim 1, wherein the compound represented by the above chemical formula 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof, or mixtures thereof inhibit(s) deposition of triglycerides in liver tissues.

5. The use according to claim 1, wherein the compound represented by the above chemical formula 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof, or mixtures thereof inhibit(s) infiltration of inflammatory cells in liver tissues.

6. The use according to claim 1, wherein the compound represented by the above chemical formula 1, pharmaceutically acceptable salts thereof, optical isomers thereof, hydrates or solvates thereof, or mixtures thereof inhibit(s) fibrosis of liver tissues.